CTLA4 and hepatocellular carcinoma: A neoadjuvant randomized trial involved nine early-stage HCC patients receiving 3 mg of nivolumab (anti-PD-L1) on the first day after 14 days and 1 mg/kg of ipilimumab (anti-CTLA-4) on day 1 after 1.5 months for 2 years.